Shares of Innate Pharma S.A. (NASDAQ:IPHA) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus price target of $10.00 for the company, according to Zacks. Zacks has also assigned Innate Pharma an industry rank of 56 out of 255 based on the ratings given to its competitors.
NASDAQ IPHA traded up $0.27 during trading hours on Tuesday, reaching $6.58. The stock had a trading volume of 1,110 shares. Innate Pharma has a 52-week low of $5.61 and a 52-week high of $6.53.
Innate Pharma Company Profile
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Featured Story: What are the Different Types of Leveraged Buyouts?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.